SAN DIEGO — Expect initial public offerings for biotechnology companies to continue to pop in the second half of 2026, driven by investors eager to back drug startups with quality clinical data in hand.
In a Monday afternoon panel at the annual meeting of the Biotechnology Innovation Organization, investors and healthcare investment bankers argued that the pace of IPOs will accelerate — a surge fueled by “the same supply-and-demand dynamics” that ignited the last boom in stock offerings, said Dan Angius, the senior managing director of new listings and global markets at Nasdaq.
“The window’s open,” said Jim Healy, a managing partner at Sofinnova Investments, in an interview with BioPharma Dive.
A baker’s dozen of venture-backed biotechnology companies have so far priced IPOs in 2026. Two, Parabilis Medicines and Kailera Therapeutics, eclipsed the previous record — held by Moderna — for the most raised in an initial share sale. Those two offerings are emblematic of what’s been a notable spike in the number of big-ticket IPOs in 2026. According to BioPharma Dive data, 11 of the year’s 13 newly public biotech companies secured at least $250 million in IPO proceeds, a total that already exceeds most years since 2018.
